Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Lactobacillus delbrueckii lactis DN111244
- Development stage
- Unknown
- Lead developer
- Danone
- Modality
- Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Administration
- Oral
01
Overview
Lactobacillus delbrueckii lactis DN111244 is a specific probiotic strain of lactic acid bacteria developed by Danone Research. It has been primarily investigated for its potential to lower plasma LDL-cholesterol levels in adults with hypercholesterolemia. The strain is typically delivered via fermented milk products. Its mechanism involves the modulation of gut microbiota and potential interference with cholesterol absorption or metabolism, although the exact biochemical pathways in humans remain a subject of research. Clinical trials have demonstrated a significant reduction in total and LDL cholesterol after short-term (e.g., 8-week) consumption of fermented milk containing this strain.
- Other names
- Lactobacillus delbrueckii subsp. lactis DN111244L. delbrueckii lactis DN111244
Beyond the preview
Go deeper on Lactobacillus delbrueckii lactis DN111244.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Lactobacillus delbrueckii lactis DN111244.